Heiner Zimmermann

1.0k total citations
20 papers, 508 citations indexed

About

Heiner Zimmermann is a scholar working on Oncology, Pathology and Forensic Medicine and Genetics. According to data from OpenAlex, Heiner Zimmermann has authored 20 papers receiving a total of 508 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Oncology, 13 papers in Pathology and Forensic Medicine and 7 papers in Genetics. Recurrent topics in Heiner Zimmermann's work include Viral-associated cancers and disorders (17 papers), Lymphoma Diagnosis and Treatment (13 papers) and Polyomavirus and related diseases (9 papers). Heiner Zimmermann is often cited by papers focused on Viral-associated cancers and disorders (17 papers), Lymphoma Diagnosis and Treatment (13 papers) and Polyomavirus and related diseases (9 papers). Heiner Zimmermann collaborates with scholars based in Germany, France and Australia. Heiner Zimmermann's co-authors include Ralf Ulrich Trappe, Hanno Riess, Ioannis Anagnostopoulos, Petra Reinke, H. Lehmkuhl, R. Neuhaus, Stephan Oertel, Peter Mollee, Véronique Leblond and Franck Morschhauser and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Heiner Zimmermann

19 papers receiving 497 citations

Peers

Heiner Zimmermann
Comparison fields: 5 of 50
  • Oncology 425
  • Pathology and Forensic Medicine 266
  • Epidemiology 87
  • Neurology 50
  • Genetics 42
Replace Teresio Motta with:
Teresio Motta Italy
Cannon Milani United States
Yvonne Perner South Africa
Zeina Al‐Mansour United States
Amelie Kinch Sweden
Pamela Vezzoli Italy
Viviana Minardi Italy
Maddalena Maresca Italy
Shehla Sheikh Canada
Yasunobu Sekiguchi Japan
Teresio Motta Italy View profile →
Citations per field, relative to Heiner Zimmermann
Heiner Zimmermann · 1×
Citations per year, relative to Heiner Zimmermann
Heiner Zimmermann · 1×

Countries citing papers authored by Heiner Zimmermann

Since Specialization
Citations

This map shows the geographic impact of Heiner Zimmermann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Heiner Zimmermann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Heiner Zimmermann more than expected).

Fields of papers citing papers by Heiner Zimmermann

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Heiner Zimmermann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Heiner Zimmermann. The network helps show where Heiner Zimmermann may publish in the future.

Co-authorship network of co-authors of Heiner Zimmermann

This figure shows the co-authorship network connecting the top 25 collaborators of Heiner Zimmermann. A scholar is included among the top collaborators of Heiner Zimmermann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Heiner Zimmermann. Heiner Zimmermann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
# Work Indexed citations
1
Adherence to Multidisciplinary Tumor Board Recommendations and Its Association with Survival: A Retrospective Observational Study of Colorectal Cancer Patients
2025 ·Journal of Gastrointestinal Cancer ·(unknown), (unknown), Heiner Zimmermann, Lena Ansmann, (unknown), Maximilian Bockhorn, Claus‐Henning Köhne, Frank Griesinger
0
2
Comparative analysis of tabelecleucel and current treatment in patients with Epstein-Barr virus-positive post-transplant lymphoproliferative disease following hematopoietic cell transplant or solid organ transplant
2024 ·Journal of Medical Economics ·Arie Barlev, Heiner Zimmermann, Norma Guzmán‐Becerra, (unknown), (unknown), (unknown), (unknown), M. Alan Brookhart
2
3
Modified risk-stratified sequential treatment (subcutaneous rituximab with or without chemotherapy) in B-cell Post-transplant lymphoproliferative disorder (PTLD) after Solid organ transplantation (SOT): the prospective multicentre phase II PTLD-2 trial
2022 ·Leukemia ·Heiner Zimmermann, Christian Koenecke, Martin Dreyling, Christiane Pott, Ulrich Dührsen, D Hahn, Norbert Meidenbauer, Ingeborg A. Hauser, Mathias Rummel, Dominik Wolf‎, Michael Heuser, Christian Schmidt, Peter Schlattmann, Matthias Ritgen, Reiner Siebert, Ilske Oschlies, Ioannis Anagnostopoulos, Ralf Ulrich Trappe
15
4
Clinical Outcomes of Solid Organ Transplant Patients with Epstein-Barr Virus-Driven (EBV +) Post-Transplant Lymphoproliferative Disorder (PTLD) Who Fail Rituximab Plus Chemotherapy: A Multinational, Retrospective Chart Review Study
2021 ·Blood ·Vikas R. Dharnidharka, (unknown), Ulrich Jaeger, (unknown), Daan Dierickx, Pengcheng Xun, (unknown), Ahmed Sawas, Natalia Sadetsky, (unknown), (unknown), Arie Barlev, Heiner Zimmermann, Ralf Ulrich Trappe
8
5
Reduction of immunosuppression combined with whole-brain radiotherapy and concurrent systemic rituximab is an effective yet toxic treatment of primary central nervous system post-transplant lymphoproliferative disorder (pCNS-PTLD): 14 cases from the prospective German PTLD registry
2021 ·Annals of Hematology ·Heiner Zimmermann, Mirko Nitsche, Christiane Pott, Petra Reinke, Nina Babel, Robert Michael Hermann, Ingeborg A. Hauser, D Hahn, Matthias Ritgen, (unknown), Wolfram Klapper, Ioannis Anagnostopoulos, Ralf Ulrich Trappe, (unknown)
8
6
Treatment stratification in B-cell PTLD after solid organ transplantation (SOT) by international prognostic index (IPI) and response to rituximab: Interim results from the PTLD-2 trial.
2020 ·Journal of Clinical Oncology ·Ralf Ulrich Trappe, Christian Koenecke, Martin Dreyling, Christiane Pott, Ulrich Duehrsen, Norbert Meidenbauer, D Hahn, Michael Heuser, Christian Schmidt, Matthias Ritgen, Reiner Siebert, Ilske Oschlies, Ioannis Anagnostopoulos, Heiner Zimmermann, (unknown)
2
7
Serum-free light chains adjusted for renal function are a potential biomarker for post-transplant lymphoproliferative disorders
2019 ·Annals of Hematology ·Richard Borrows, (unknown), Paul Cockwell, Frank Braun, I. Anagnostopoulos, Hanno Riess, Heiner Zimmermann, Ralf Ulrich Trappe
1
8
PF719 CLINICAL OUTCOMES OF SOLID ORGAN TRANSPLANT PATIENTS WITH EBV+PTLD WHO FAIL FIRST-LINE RITUXIMAB OR RITUXIMAB PLUS CHEMOTHERAPY: AN ANALYSIS OF GERMAN PTLD REGISTRY
2019 ·HemaSphere ·Heiner Zimmermann, Hairong Xu, Arie Barlev, (unknown), (unknown), Willis H. Navarro, Ralf Ulrich Trappe
2
9
Burden of Hospitalizations Due to Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disorder (EBV+PTLD) in Patients Who Failed First Line Rituximab or Rituximab Plus Chemotherapy Following Solid Organ Transplant (Post-SOT): A Retrospective Chart Review Study of German PTLD Registry
2019 ·Blood ·Heiner Zimmermann, Hairong Xu, Arie Barlev, Yang Zhang, (unknown), Crystal Watson, Ralf Ulrich Trappe
1
10
End-of-Treatment Positron Emission Tomography After Uniform First-Line Therapy of B-Cell Posttransplant Lymphoproliferative Disorder Identifies Patients at Low Risk of Relapse in the Prospective German PTLD Registry
2017 ·Transplantation ·Heiner Zimmermann, Timm Denecke, Martin Dreyling, Christiane Franzius, Petra Reinke, Marion Subklewe, Holger Amthauer, Michael Kneba, Hanno Riess, Ralf Ulrich Trappe
18
11
Fcγ-Receptor IIIA Polymorphism p.158F Has No Negative Predictive Impact on Rituximab Therapy with and without Sequential Chemotherapy in CD20-Positive Posttransplant Lymphoproliferative Disorder
2014 ·Journal of Immunology Research ·Heiner Zimmermann, (unknown), Jamie P. Nourse, Maher K. Gandhi, Petra Reinke, R. Neuhaus, Mohsen Karbasiyan, Barbara C. Gärtner, Ioannis Anagnostopoulos, Hanno Riess, Ralf Ulrich Trappe, Stephan Oertel
2
12
EBV and posttransplantation lymphoproliferative disease: what to do?
2013 ·Hematology ·Heiner Zimmermann, Ralf Ulrich Trappe
32
13
Burkitt post‐transplantation lymphoma in adult solid organ transplant recipients
2012 ·Cancer ·Heiner Zimmermann, Petra Reinke, R. Neuhaus, H. Lehmkuhl, Stephan Oertel, (unknown), M. Planker, Barbara C. Gärtner, Dido Lenze, Ioannis Anagnostopoulos, Hanno Riess, Ralf Ulrich Trappe
22
14
Interim analysis of the largest prospective trial to date in adult CD20-positive post-transplant lymphoproliferative disorder (PTLD): Introducing risk-stratified sequential treatment (RSST).
2012 ·Journal of Clinical Oncology ·Ralf Ulrich Trappe, Daan Dierickx, Petra Reinke, R. Neuhaus, Franck Morschhauser, Jan Maciej Zaucha, Peter Mollee, Heiner Zimmermann, Martin Dreyling, Ulrich Duehrsen, Gregor Verhoef, H. Lehmkuhl, Marion Subklewe, (unknown), Thomas Tousseyn, Corrado Tarella, Véronique Leblond, Ioannis Anagnostopoulos, Hanno Riess, Sylvain Choquet, (unknown)
3
15
Plasmablastic Posttransplant Lymphoma
2012 ·Transplantation ·Heiner Zimmermann, Ilske Oschlies, (unknown), Christiane Pott, Hans H. Neumayer, H. Lehmkuhl, Ingeborg A. Hauser, Martin Dreyling, Michael Kneba, Barbara C. Gärtner, Ioannis Anagnostopoulos, Hanno Riess, Wolfram Klapper, Ralf Ulrich Trappe
28
16
IL-6 and IL-10 in post-transplant lymphoproliferative disorders development and maintenance: a longitudinal study of cytokine plasma levels and T-cell subsets in 38 patients undergoing treatment
2011 ·Transplant International ·Carl Hinrichs, (unknown), Heiner Zimmermann, Dennis Eurich, R. Neuhaus, Peter Schlattmann, Nina Babel, Hanno Riess, Barbara C. Gärtner, Ioannis Anagnostopoulos, Petra Reinke, Ralf Ulrich Trappe
23
17
Plasmacytoma-like post-transplant lymphoproliferative disorder, a rare subtype of monomorphic B-cell post-transplant lymphoproliferation, is associated with a favorable outcome in localized as well as in advanced disease: a prospective analysis of 8 cases
2011 ·Haematologica ·Ralf Ulrich Trappe, Heiner Zimmermann, (unknown), Petra Reinke, Martin Dreyling, Andreas Pascher, H. Lehmkuhl, Barbara C. Gärtner, Ioannis Anagnostopoulos, Hanno Riess
47
18
Therapeutic options in post-transplant lymphoproliferative disorders
2011 ·Therapeutic Advances in Hematology ·Heiner Zimmermann, Ralf Ulrich Trappe
26
19
Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial
2011 ·The Lancet Oncology ·Ralf Ulrich Trappe, Stephan Oertel, Véronique Leblond, Peter Mollee, Monica Sender, Petra Reinke, R. Neuhaus, H. Lehmkuhl, Heinz A. Horst, Gilles Salles, Franck Morschhauser, Arnaud Jaccard, Thierry Lamy, Malte Leithäuser, Heiner Zimmermann, Ioannis Anagnostopoulos, Martine Raphaël, Hanno Riess, Sylvain Choquet
252
20
Effect of dexamethasone on pulmonary and renal angiotensin-converting enzyme concentration in fetal sheep during late gestation
2003 ·American Journal of Obstetrics and Gynecology ·Heiner Zimmermann, David S. Gardner, Juanita K. Jellyman, Abigail L. Fowden, Dino A. Giussani, Alison J. Forhead
16

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Teresio Motta Breakdown of academic impact, for papers by Cannon Milani Breakdown of academic impact, for papers by Yvonne Perner Breakdown of academic impact, for papers by Zeina Al‐Mansour Breakdown of academic impact, for papers by Amelie Kinch Breakdown of academic impact, for papers by Pamela Vezzoli Breakdown of academic impact, for papers by Viviana Minardi Breakdown of academic impact, for papers by Maddalena Maresca Breakdown of academic impact, for papers by Shehla Sheikh Breakdown of academic impact, for papers by Yasunobu Sekiguchi
Rankless by CCL
2026